Learn About Eunuchoidism Familial Hypogonadotropic
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Duke Raleigh Hospital
Aaron Lentz is an Urologist in Raleigh, North Carolina. Dr. Lentz is rated as an Advanced provider by MediFind in the treatment of Eunuchoidism Familial Hypogonadotropic. His top areas of expertise are Stress Urinary Incontinence, Urinary Incontinence, Erectile Dysfunction (ED), Prostatectomy, and Ureteroscopy. Dr. Lentz is currently accepting new patients.
Atrium Health Primary Care Cabarrus Family Medicine
David Tignor is a primary care provider, practicing in Family Medicine in Concord, North Carolina. Dr. Tignor is rated as an Advanced provider by MediFind in the treatment of Eunuchoidism Familial Hypogonadotropic. His top areas of expertise are Hypertension, Familial Hypertension, Glucocorticoid-Remediable Aldosteronism, and High Cholesterol.
Giovanni Corona practices in Bologna, Italy. Mr. Corona is rated as an Elite expert by MediFind in the treatment of Eunuchoidism Familial Hypogonadotropic. His top areas of expertise are Hypogonadism, Erectile Dysfunction (ED), Hypogonadotropic Hypogonadism, Hormone Replacement Therapy (HRT), and Prostatectomy.
Summary: This is a 52-week open label single arm study to investigate the effects of XYOSTED, as testosterone replacement therapy, on adolescent males with either primary or secondary hypogonadism. The study aims to determine the effectiveness of XYOSTED measured by continuation or induction of puberty in addition to XYOSTED dosage, safety and testosterone levels.
Summary: To assess endothelial dysfunction in young men (aged 30-50) with vasculogenic ED identified through penile Doppler ultrasound. To evaluate changes in endothelial function using EndoPAT before and 3-6 months after daily low-dose phosphodiesterase type 5 (PDE5) inhibitor therapy. To investigate endothelial function alterations in hypogonadal patients before and 3-6 months after initiating testostero...